EU Tepid on Biden Call to Waive Intellectual Property Rights for Covid-19 Vaccines
May 08 2021 - 2:02PM
Dow Jones News
By Eric Sylvers
European Union leaders pushed back against President Biden's
call to wave intellectual property rights for Covid-19 vaccines,
saying exporting more shots would be a faster way to help poor
countries struggling to contain the virus.
The EU is ready to discuss the U.S. stance, which the Biden
administration voiced earlier this week, when there is a concrete
proposal, European Council President Charles Michel said at a
summit in Portugal on Saturday.
"We don't think in the short term that it's the magic bullet,"
Mr. Michel said of the proposal to lift patent protections, which
could enable companies in developing countries and others to
manufacture their own versions of Covid-19 vaccines.
German Chancellor Angela Merkel also rejected the idea of
waiving Covid vaccine patents. She said a waiver wouldn't make more
vaccine doses available and countries should protect "the power of
innovation" and patent protections. Germany is home to BioNTech SE,
which co-developed a vaccine with Pfizer Inc., and CureVac NV,
which is running clinical trials for a Covid vaccine.
The Biden administration's embrace of the waiver sent the EU
scrambling to explain its plans to help poor countries when the
U.S. and Europe are quickly vaccinating their populations. The more
the virus spreads, the more likely it is to mutate into a
vaccine-resistant strain.
To help countries like India facing a surge in infections and
deaths, richer countries should concentrate on increasing vaccine
production around the world in facilities already making the
vaccine, EU leaders said. Rich countries should also export more
vaccine doses, Ms. Merkel and other EU leaders said.
The EU has exported more than 200 million vaccine doses, the
same amount that has have been delivered to Europeans, EU
Commission President Ursula von der Leyen said this week. The U.S.
government has used the Defense Production Act to force private
companies to first honor contracts with the government before they
meet orders from other companies or countries. The U.S. has
stockpiled millions of doses of the AstraZeneca vaccine even though
the shot isn't approved for use in the country. On April 26, the
Biden administration said it would share as many as 60 million
AstraZeneca doses with the rest of the world.
Late last year, India and South Africa proposed waving patents
for Covid-19 vaccines, treatments and diagnostics. More than 100
countries have supported the proposal, with the U.S. joining the
chorus this week.
Even with the U.S. support, challenges remain before the patent
wavier could significantly increase vaccine production. It might
take several months to define the details of any plan, with
potential sticking points including how drugmakers would transfer
technical know-how to manufacturers without vaccine expertise. Six
months could pass before plants produce their first doses of a
vaccine, according to some public health experts.
Production could also be hampered by the need to fund new
machinery and adapt the production process, according to some Covid
vaccine manufacturers that have opposed the waiver idea.
Write to Eric Sylvers at eric.sylvers@wsj.com
(END) Dow Jones Newswires
May 08, 2021 13:47 ET (17:47 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024